Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celldex Therapeutics (CLDX) Intangibles (2016 - 2025)

Celldex Therapeutics (CLDX) has 16 years of Intangibles data on record, last reported at $27.2 million in Q4 2025.

  • For Q4 2025, Intangibles changed 0.04% year-over-year to $27.2 million; the TTM value through Dec 2025 reached $27.2 million, changed 0.04%, while the annual FY2025 figure was $27.2 million, 0.04% changed from the prior year.
  • Intangibles reached $27.2 million in Q4 2025 per CLDX's latest filing, roughly flat from $27.2 million in the prior quarter.
  • Across five years, Intangibles topped out at $30.7 million in Q1 2021 and bottomed at $27.2 million in Q3 2021.
  • Average Intangibles over 5 years is $27.7 million, with a median of $27.2 million recorded in 2022.
  • Peak YoY movement for Intangibles: fell 11.4% in 2021, then grew 0.04% in 2022.
  • A 5-year view of Intangibles shows it stood at $27.2 million in 2021, then increased by 0.04% to $27.2 million in 2022, then changed by 0.0% to $27.2 million in 2023, then fell by 0.04% to $27.2 million in 2024, then increased by 0.04% to $27.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Intangibles were $27.2 million in Q4 2025, $27.2 million in Q4 2024, and $27.2 million in Q3 2024.